New treatmnet for metastatic CRPC in a pipeline

Cool...maybe another tool in the box.

Here is a summary of the press release:

**Overview**
Johnson & Johnson announced promising preliminary results from a Phase 1b study evaluating its investigational drug **pasritamig** (JNJ-78278343) in combination with the chemotherapy drug **docetaxel** for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings were presented at the 2026 ASCO Genitourinary Cancers Symposium.

**How Pasritamig Works**
Pasritamig is a first-in-class bispecific T-cell engaging antibody. It works by binding to CD3 on T cells and human kallikrein 2 (KLK2)—a target highly specific to prostate tissue—on cancer cells. This redirects the body’s immune system to specifically attack the prostate cancer cells while minimizing damage to healthy tissues.

**Key Efficacy Results**
The combination showed deep and sustained clinical activity, particularly in reducing prostate-specific antigen (PSA) levels:

* **Overall Patients:** 64.7% achieved a PSA reduction of 50% or more, and 39.2% achieved a reduction of 90% or more.
* **Taxane-Naïve Patients:** Efficacy was even higher, with 75% achieving a ≥50% PSA reduction and 53.6% achieving a ≥90% reduction.
* **Taxane-Naïve Patients with Bone-Only Disease:** Showed the strongest response, with 88.2% achieving a ≥50% PSA reduction and 76.5% achieving a ≥90% reduction.

**Safety Profile**
The safety profile of the combination was favorable and consistent with what is typically seen with docetaxel alone. There were no new or unexpected safety signals.

* Grade 3 or higher treatment-related adverse events were primarily attributed to docetaxel (29.4%) rather than pasritamig (2%).
* No patients experienced cytokine release syndrome (CRS) or treatment-related deaths.

**Next Steps**
Because of these encouraging results—combining immunotherapy with chemotherapy where previous approaches have fallen short—J&J is advancing pasritamig into two Phase 3 trials. The drug has also already received Breakthrough Therapy Designation in China and Fast Track designation from the U.S. FDA.

@smoore4

Thanks Smoore for the summary - it might be easier for some to read that. 👍

LOVE the news…hate the idea that J&J has anything to do it. After reading No More Tears, I would be wary of any drug J&J produces.
So far the amount of lives they’ve taken or ruined far outweigh those which have been saved. Read the book and WEEP for the fraud, dishonesty and utter disdain for morality embodied by this ‘quintessential’ American company.
Makes the Sackler family look like the Von Trapps!!
Phil

@heavyphil
May this be their chance for redemption ✨

@surftohealth88 This book is right up your alley, Surf!
If you think your current situation makes you a tad angry, reading this book just might put you at the next level.
I thought I was pretty cynical and sanguine about the relationships of Big Pharma and the various parts of the medical/scientific community…but when you add that special sauce of ‘politics’ and influence peddling, it makes me feel like a naive bumpkin…what a f****ed up world!!
Phil